260 related articles for article (PubMed ID: 37148547)
21. Comparative effectiveness of sodium-glucose cotransporter-2 inhibitors for new-onset gastric cancer and gastric diseases in patients with type 2 diabetes mellitus: a population-based cohort study.
Chou OHI; Chauhan VK; Chung CTS; Lu L; Lee TTL; Ng ZMW; Wang KKW; Lee S; Liu H; Pang RTK; Kaewdech A; Cheung BMY; Tse G; Zhou J
Gastric Cancer; 2024 Jun; ():. PubMed ID: 38856768
[TBL] [Abstract][Full Text] [Related]
22. Risk of hospitalization and death associated with sodium glucose cotransporter-2 inhibitors: A comparison with five other classes of antidiabetic drugs.
Alkabbani W; Gamble JM; Eurich DT; Minhas-Sandhu JK; Shah BR; Alsabbagh MW; Zongo A
Diabetes Metab; 2022 Mar; 48(2):101305. PubMed ID: 34808344
[TBL] [Abstract][Full Text] [Related]
23. The epidemiology of ketosis and low bicarbonate concentration in inpatients treated with sodium-glucose linked cotransporter inhibitors or dipeptidyl peptidase-4 inhibitors.
Huang W; Whitelaw J; Kishore K; Neto AS; Holmes NE; Marhoon N; Bellomo R; Ekinci EI
J Diabetes Complications; 2023 Aug; 37(8):108522. PubMed ID: 37311358
[TBL] [Abstract][Full Text] [Related]
24. Reduction in cardiovascular disease events in patients with type 2 diabetes mellitus treated with a sodium-glucose cotransporter 2 inhibitor versus a dipeptidyl peptidase-4 inhibitor: A real-world retrospective administrative database analysis in Japan.
Kashiwagi A; Shoji S; Onozawa S; Kosakai Y; Waratani M; Ito Y
J Diabetes Investig; 2022 Jul; 13(7):1175-1189. PubMed ID: 35243799
[TBL] [Abstract][Full Text] [Related]
25. Sodium-Glucose Cotransporter 2 Inhibitors and Nephrolithiasis Risk in Patients With Type 2 Diabetes.
Paik JM; Tesfaye H; Curhan GC; Zakoul H; Wexler DJ; Patorno E
JAMA Intern Med; 2024 Mar; 184(3):265-274. PubMed ID: 38285598
[TBL] [Abstract][Full Text] [Related]
26. Risk of amputations associated with SGLT2 inhibitors compared to DPP-4 inhibitors: A propensity-matched cohort study.
Adimadhyam S; Lee TA; Calip GS; Smith Marsh DE; Layden BT; Schumock GT
Diabetes Obes Metab; 2018 Dec; 20(12):2792-2799. PubMed ID: 29971914
[TBL] [Abstract][Full Text] [Related]
27. Lower cardiorenal risk with sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes without cardiovascular and renal diseases: A large multinational observational study.
Birkeland KI; Bodegard J; Banerjee A; Kim DJ; Norhammar A; Eriksson JW; Thuresson M; Okami S; Ha KH; Kossack N; Mamza JB; Zhang R; Yajima T; Komuro I; Kadowaki T
Diabetes Obes Metab; 2021 Jan; 23(1):75-85. PubMed ID: 32893440
[TBL] [Abstract][Full Text] [Related]
28. Risk of morbidity and mortality in patients with type 2 diabetes treated with sodium-glucose cotransporter-2 inhibitor and/or dipeptidyl peptidase-4 inhibitor: a nationwide study.
Sütő G; Molnár GA; Rokszin G; Fábián I; Kiss Z; Szekanecz Z; Poór G; Jermendy G; Kempler P; Wittmann I
BMJ Open Diabetes Res Care; 2021 Jan; 9(1):. PubMed ID: 33472796
[TBL] [Abstract][Full Text] [Related]
29. Sodium-glucose co-transporter-2 inhibitors and the risk of urosepsis: A multi-site, prevalent new-user cohort study.
Fisher A; Fralick M; Filion KB; Dell'Aniello S; Douros A; Tremblay É; Shah BR; Ronksley PE; Alessi-Severini S; Hu N; Bugden SC; Ernst P; Lix LM;
Diabetes Obes Metab; 2020 Sep; 22(9):1648-1658. PubMed ID: 32383792
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and safety of combination therapy with SGLT2 and DPP4 inhibitors in the treatment of type 2 diabetes: A systematic review and meta-analysis.
Cho YK; Kang YM; Lee SE; Lee J; Park JY; Lee WJ; Kim YJ; Jung CH
Diabetes Metab; 2018 Nov; 44(5):393-401. PubMed ID: 29449146
[TBL] [Abstract][Full Text] [Related]
31. Comparative effectiveness of sodium-glucose co-transporter-2 inhibitors and dipeptidyl peptidase-4 inhibitors on liver function in patients with type 2 diabetes in Japan: A real-world data analysis.
Takahashi H; Asakawa K; Kosakai Y; Lee T; Rokuda M
Diabetes Obes Metab; 2024 Mar; 26(3):997-1007. PubMed ID: 38086547
[TBL] [Abstract][Full Text] [Related]
32. Risk of ICU Admission and Related Mortality in Patients With Sodium-Glucose Cotransporter 2 Inhibitors and Dipeptidyl Peptidase-4 Inhibitors: A Territory-Wide Retrospective Cohort Study.
Ng PY; Ng AK; Ip A; Wu MZ; Guo R; Yiu KH
Crit Care Med; 2023 Aug; 51(8):1074-1085. PubMed ID: 37026864
[TBL] [Abstract][Full Text] [Related]
33. Cardiovascular outcomes with SGLT2 inhibitors versus DPP4 inhibitors and GLP-1 receptor agonists in patients with heart failure with reduced and preserved ejection fraction.
Gonzalez J; Bates BA; Setoguchi S; Gerhard T; Dave CV
Cardiovasc Diabetol; 2023 Mar; 22(1):54. PubMed ID: 36899387
[TBL] [Abstract][Full Text] [Related]
34. Effect of SGLT2 inhibitors versus DPP4 inhibitors or GLP-1 agonists on diabetic foot-related extremity amputation in patients with T2DM: A meta-analysis.
Du Y; Bai L; Fan B; Ding H; Ding H; Hou L; Ma H; Xing N; Wang F
Prim Care Diabetes; 2022 Feb; 16(1):156-161. PubMed ID: 34930687
[TBL] [Abstract][Full Text] [Related]
35. Restricted Mean Survival Time Analysis to Estimate SGLT2i-Associated Heterogeneous Treatment Effects on Primary and Secondary Prevention of Cardiorenal Outcomes in Patients With Type 2 Diabetes in Taiwan.
Peng ZY; Yang CT; Kuo S; Wu CH; Lin WH; Ou HT
JAMA Netw Open; 2022 Dec; 5(12):e2246928. PubMed ID: 36520437
[TBL] [Abstract][Full Text] [Related]
36. Association of SGLT2 inhibitors with lower incidence of death in type 2 diabetes mellitus and causes of death analysis.
Chung MC; Hsu HT; Chang CH; Hung PH; Hsiao PJ; Wu LY; Wu MJ; Shieh JJ; Chung CJ
Sci Rep; 2022 Jun; 12(1):10147. PubMed ID: 35710921
[TBL] [Abstract][Full Text] [Related]
37. Risk of lower extremity amputations in patients with type 2 diabetes using sodium-glucose co-transporter 2 inhibitors.
Zerovnik S; Kos M; Locatelli I
Acta Diabetol; 2022 Feb; 59(2):233-241. PubMed ID: 34609620
[TBL] [Abstract][Full Text] [Related]
38. The impact of sodium-glucose co-transporter-2 inhibitors on dementia and cardiovascular events in diabetic patients with atrial fibrillation.
Chen YY; Chang HC; Lin YJ; Chien KL; Hsieh YC; Chung FP; Lin CH; Lip GYH; Chen SA
Diabetes Metab Res Rev; 2024 Feb; 40(2):e3775. PubMed ID: 38340046
[TBL] [Abstract][Full Text] [Related]
39. Comparison between SGLT2 inhibitors and DPP4 inhibitors added to insulin therapy in type 2 diabetes: a systematic review with indirect comparison meta-analysis.
Min SH; Yoon JH; Hahn S; Cho YM
Diabetes Metab Res Rev; 2017 Jan; 33(1):. PubMed ID: 27155214
[TBL] [Abstract][Full Text] [Related]
40. Second-Line Pharmaceutical Treatments for Patients with Type 2 Diabetes.
Vashisht R; Patel A; Dahm L; Han C; Medders KE; Mowers R; Byington CL; Koliwad SK; Butte AJ
JAMA Netw Open; 2023 Oct; 6(10):e2336613. PubMed ID: 37782497
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
